@proteinqure

Dare to deliver. Peptide-based drug delivery.

 Toronto, Ontario
proteinqure.com
Joined October 2017
  • Tweets313
  • Following59
  • Followers1.2K
148Media
We shared an exclusive update at the @BoulderPeptide Symposium, where Julie Owen presented v1.1 of our peptide monomer database, expanding the resource from ~2,500 to nearly 5,000 peptide monomers and adding new ways to explore, search, and source this chemical space. See link 👇
1
1
1
121
📦 Download & cite the dataset on Zenodo: zenodo.org/records/21684534 Questions or contributions: [email protected]

Monomer database datasets

The Monomer Database is a curated, openly licensed resource for peptide and macrocycle design. 2,488 chemically standardized canonical and non-canonical peptide monomers spanning α/β/γ/δ/ε backbones...

zenodo.org
2
53
Glioblastoma almost always recurs. So we're using its own biology against it: a peptide-siRNA conjugate targeting SORT1. >1,000 sequences → ML triage → 2 leads with strong knockdown. Then we added chemo. A poster worth seeing. Shannon Tsai, Mon Oct 12, 4:30–7:30pm. @OTSociety
1
1
4
231
Find us at #BIOEurope in Cologne, Germany on Nov 9 to 11. Our CSO & Co-Founder Christopher Ing will be there to talk ML for peptides, cyclic peptide therapeutics, peptide-oligo conjugates and more. Tackle targeted delivery with us. Reach out here or via the partnering portal.
56
Inverse folding traditionally stops at 20 amino acids. AtomWeaver dares to deliver more. It builds side chains atom by atom, then matches identity against a library. Adding a new NCAA is easy, no retraining needed. Peptide design with a vocabulary you can keep expanding. Paper👇
1
2
5
419
📄 Preprint: biorxiv.org/content/10.64898… 💻 Model: github.com/ProteinQure/atomw…

AtomWeaver: Multi-Component Flow Matching with a Structured Geometric Prior Facilitates Non-Canon...

Fixed-backbone sequence discovery, or inverse folding , is a critical recurring task in the development of new polypeptide therapeutics. Once promising backbones are established for a target pocket,...

biorxiv.org
2
52
Next week: a major update to our open-source monomer database + explorer! Now featuring ~4,000 peptide monomers, launching alongside our talk at @BoulderPeptide, where Julie Owen will take us on a guided tour through chemical space. Another surprise too, so watch this space!👀
1
2
6
404
📦 Download & cite the dataset on Zenodo: zenodo.org/records/21684534 Questions or contributions: [email protected]

Monomer database datasets

The Monomer Database is a curated, openly licensed resource for peptide and macrocycle design. 2,488 chemically standardized canonical and non-canonical peptide monomers spanning α/β/γ/δ/ε backbones...

zenodo.org
1
1
80
We're at Summer #RosettaCon 2026 in Seattle! 🧠 @AnitaKNivedha presented on our computational design of peptide brain shuttles targeting TfR1 and CD98hc. If you're attending, connect with us to talk peptide design, BBB delivery, or computational biology!
1
2
183
Great visit from MP @maggiechidvn today! She toured the PQ office and learned how we're accelerating drug discovery and clinical trials. Grateful for federal leadership engaging with Canadian biotech innovation. 🧬🇨🇦
1
1
133
Somewhere in a vendor catalog is the monomer your peptide program needs. Good luck finding it. We built the Peptide Monomer Explorer: 2,400+ monomers, chemically standardized, each with a commercial source. Explore instead of hunt. monomers.proteinqure.com
2
1
1
5
807
BlogPost: proteinqure.com/monomers-blo… GitHub: github.com/ProteinQure/monom…
1
68
With support from FedDev Ontario, @ProteinQure is advancing an AI-powered drug discovery platform designed to improve targeted drug delivery, helping make cancer treatments safer, more effective and easier to produce.
1
1
174
Heading to #BIO2026? Our CEO, @lucasfolds, will be onsite meeting with partners, investors, and biotech leaders to discuss PQ203 and AI-designed peptide therapeutics. Interested in connecting? Reach out to @lucasfolds.
220
Our CEO, @lucasfolds, joined @metromorning last week to talk about ProteinQure's Phase 1 clinical trial and the promise of AI-designed peptide therapeutics. Missed it? Listen here: 🎧cbc.ca/listen/live-radio/1-3…
1
113
We presented PQ203 updates at #ASCO26. This Phase 1 study of our first-in-class, machine-learning designed peptide-drug conjugate targeting SORT1 in advanced solid tumors is supported by a strong team of investigators and collaborators. Abstract TPS3171: asco.org/abstracts-presentat…
2
137
AI therapeutics can be homegrown in Canada—from algorithm to patient. Proud that ProteinQure received $1.8M from FedDev Ontario, announced by @EvanLSolomon, to advance targeted drug delivery and accelerate safer, cost-effective treatments for patients.
2
254
ProteinQure CEO Lucas will present at #TIDESUSA2026 on our peptide-oligonucleotide conjugate platform for siRNA delivery to the CNS, including preclinical non-human primate data and work toward BBB-crossing peptides.
2
147
ProteinQure presented at the 3rd Annual Peptide-Based Therapeutics Summit 2026. Maryna Gorelik, Principal Scientist, shared our work on peptide-drug conjugates for targeted tissue and cell type delivery, including BBB shuttle strategies for chemically-modified oligonucleotides.
130
Thrilled to be featured in @uoftmagazine! Highlighting our PQ203 clinical trial and the AI-driven peptide design platform powering next-gen therapeutics 🚀 Read the article here: magazine.utoronto.ca/researc…

A Better Way to Build Cancer Drugs? | U of T Magazine - U of T Magazine

Using artificial intelligence combined with peptide design, a U of T–linked startup takes its first treatment into clinical trials Read More

magazine.utoronto.ca
3
120
Load more